Summary:
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Qualified Participants Must:
• Be 40 - 80 years old
• Be diagnosed with COPD for at least 1 year with new or increased symptoms
• Be a current or former tobacco smoker
• Have a history of smoking at least 20 cigarettes per day for at least 10 years
Qualified Participants May Receive:
Up to $3,200 for time and travel